Exact Sciences Corp (NASDAQ: EXAS) kicked off on Monday, down -4.16% from the previous trading day, before settling in for the closing price of $50.46. Over the past 52 weeks, EXAS has traded in a range of $39.97-$72.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -54.24% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 90.85%. With a float of $186.20 million, this company’s outstanding shares have now reached $188.59 million.
In an organization with 7000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 68.19%, operating margin of -36.55%, and the pretax margin is -36.39%.
Exact Sciences Corp (EXAS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Exact Sciences Corp is 1.29%, while institutional ownership is 97.50%. The most recent insider transaction that took place on Jul 16 ’25, was worth 433,605. Before that another transaction happened on Jun 13 ’25, when Company’s Director sold 3,207 for $53.20, making the entire transaction worth $170,612. This insider now owns 72,759 shares in total.
Exact Sciences Corp (EXAS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 90.85% per share during the next fiscal year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Take a look at Exact Sciences Corp’s (EXAS) current performance indicators. Last quarter, stock had a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.23. Likewise, its price to free cash flow for the trailing twelve months is 46.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.50, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach 0.37 in one year’s time.
Technical Analysis of Exact Sciences Corp (EXAS)
Let’s dig in a bit further. During the last 5-days, its volume was 2.06 million. That was inferior than the volume of 2.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 7.42%.
During the past 100 days, Exact Sciences Corp’s (EXAS) raw stochastic average was set at 44.84%, which indicates a significant increase from 0.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.07 in the past 14 days, which was lower than the 2.15 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $54.16, while its 200-day Moving Average is $54.56.
